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ABSTRACT
Chitosan has unique physicochemical and biological features that suggest it as a good candidate for the development of safe and effective drug delivery 
systems. Linking drug molecules with chitosan through a functional spacer enables formulation of prodrugs that have appropriate pharmacological 
activities at specific desired sites. The development of formulations of targeted delivery systems for the chemotherapeutic agents, especially those 
with unfavorable pharmacokinetic features, like paclitaxel (PTX), can potentially alleviate the systemic cytotoxicity as well as directing therapy to 
the specific lesions. The main aim of this literature review is to critically evaluate the use of chitosan microspheres as a drug delivery system to 
enhance PTX distribution and efficacy in specific targeted sites.
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INTRODUCTION
One of the most significant current diseases today is cancer. It is a 
leading cause of death worldwide [1]. Many strategies are committed 
to cure cancer including chemotherapy, surgery, and radiotherapy. 
However, these therapies have various types serious adverse effects 
such as hair loss, nausea, vomiting, fatigue, sleep problems, loss of 
appetite, and anemia [2,3]. During the clinical phase of the disease, most 
of the approved drugs failed to meet the targeted clinical responses, 
mostly due to inability to accumulate at the target site of action, where 
significant amounts distributed in normal tissues or organs rather than 
the diseased one; this will be accompanied with emergence of severe 
side effects [4]. In this regard, the most effective approach to avoid this 
problem is through utilizing the targeted drug delivery systems, where 
the active moieties were released and trapped within the targeted site 
of action. This approach may fulfill the criteria of patient compliance 
and increase the efficacy of the active agents through improving 
their pharmacokinetic properties [5,6]. In each drug delivery system, 
there are three major components: An active ingredient, targeting 
chromophore, and carrier system. The active drug could be incorporated 
either by passive absorption or chemical conjugation into the carrier 
system. Meanwhile, the choice of a proper carrier molecule represents a 
significant importance due to its influence on both the pharmacokinetic 
and pharmacodynamic properties of the active agent [7]. Novel 
polymeric drug delivery systems were incorporated as a novel approach 
for dispensing chemotherapeutic agents and have many advantages 
including availability of various biocompatible polymers that enables 
formulation of many pharmaceutical dosage forms that utilize polymer-
based drug carriers, such as microspheres, hydrogels, micelles, and 
nanosystems [8,9]. The conventional formulations of chemotherapeutic 
agents have inherited critical drawbacks that include high toxicity 
rates due to indiscriminate distribution toward normal and diseased 
cells after systemic administration. Moreover, poor aqueous solubility 
of most anticancer agents needs to use organic solvents during their 
formulation, with associated rise of undesirable effects such as vascular 
irritation and respiratory distress [10,11]. Therefore, utilizing an 
effective carrier system that can be loaded with large amounts of the 
active drug and specifically targeting cancer cells is considered as an 
interesting idea for successful cancer treatment.
A wide range of chemotherapeutic agents has been formulated using 
the approach of loading in a carrier system for many reasons. Chitosan-
loaded drugs represent the bases of delivering hydrophobic small 
molecular drugs to a specific site of action [12]; this type of delivery 
systems includes a water-soluble polymer conjugated to the active drug 
through a biodegradable spacer, which is stable at circulation while 
cleaved at the targeted cell spontaneously or by enzymatic catalysis. 
Based on this concept, many delivery systems are formulated and 
approved for clinical use. There are many examples for this system 
among them is gemcitabine-loaded chitosan microspheres, where the 
carrier system improves cytotoxicity of the active agent [13]. Similarly, 
nanoparticles of gemcitabine were prepared to utilize chitosan polymer, 
and evaluation of this formula showed that gemcitabine-loaded 
particles demonstrated optimum size and maximum entrapment 
properties [14]. Moreover, the recently prepared methotrexate (MTX)-
loaded chitosan-based microspheres proved to be a promising drug 
delivery system that improves inject ability and compatibility, in 
addition to prolongation drug releasing time of injectable MTX [15]. 
Meanwhile, the magnetic chitosan-MTX microspheres prepared by 
suspension cross-linking technique demonstrated great potential 
application in magnetic targeting drug delivery technology [16]. 
Microspheres of chitosan cross-linked with polyethylene glycol were 
prepared by emulsion cross-linking and found to slow the release of 
5-fluorouracil up to 24hr to colonic region and increased its anticancer 
activity [17]. Furthermore, various formulations of chitosan-based 
models loaded with doxorubicin and cisplatin were prepared and 
evaluated, and the results demonstrated promising features for these 
newly developed formulations to improve efficacy and safety of these 
cytotoxic agents [18-20].
At present, chitosan-based drug delivery systems are widely utilized 
to target specific sites within the gastrointestinal (GI) tract since this 
approach can protect the highly sensitive active moieties from the 
unfavored conditions of the upper GI compartment. This approach 
enables the release of the active agent at specific sites (e.g., the 
colon), probably through hydrolysis of the glycosidic linkage with 
chitosan by the microflora [21]. In this regard, among the most 
investigated chemotherapeutic agents is paclitaxel (PTX), and many 
evidence showed that cellular association and cytotoxicity of PTX 
were significantly enhanced when administered as chitosan-loaded 
formula [22]. However, despite its many clinical advantages, PTX suffers 
from many limitations including low bioavailability due to its poor 
solubility [23]. Recently, scientists have shown an increased interest in 
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formulating low therapeutic index drugs (e.g., PTX) in smart delivery 
systems, such as microspheres, to overcome such limitations and to 
avoid the fluctuations in plasma concentration of the drug, which lead 
to over or under medication [24]. Smart delivery systems are designed 
for the aim of providing safer and more efficient ways to deliver 
drugs with minimum adverse effects and/or enhanced therapeutic 
efficacy of the drug. These new drug delivery systems have become 
very important and might be more important than the drug itself. As a 
drug carrier, chitosan has been widely used as a drug delivery system 
for different types of biologically active molecules, including peptides, 
genes and small molecular weight drugs [25-27]. At present, many 
molecular targets are discovered and well characterized for therapeutic 
targeting, and the majority of clinically approved drugs belongs to the 
low molecular weight type [28]. Accordingly, effective delivery of these 
drugs, especially those with low therapeutic index or wide range of 
toxic effects, is considered as a growing challenge for researcher in 
pharmaceutical industry. The main aim of this literature review is to 
critically testing the use of chitosan microspheres as a drug delivery 
system to enhance PTX distribution and efficacy in specific targeted 
sites.
CHITOSAN MICROSPHERES
Microspheres are one of the most advanced approaches of controlled 
drug delivery systems [29]. They can be defined as spherical, small, 
biodegradable, and biocompatible particles [30] more than 1 µm 
(<100 µm) in size [31]. Due to the microsphere’s small particle size, it has 
large surface area leading to a higher diffusion rate and better control of 
drug release [31]. Furthermore, there are several types of microspheres 
such as polymeric microspheres [32], radioactive microspheres [33], 
floating microspheres [34], and bioadhesive microspheres [35]. 
Microspheres have different applications in medical practice. In most 
instances, they are utilized as carriers and target delivery systems for 
many drug molecules, and for slow releasing of drugs over the required 
period to maintain effective drug concentrations at specific biological 
targets. In addition, microspheres have many other applications 
in food, medical devices, and water purification techniques [36]. 
Moreover, microspheres have many applications in pharmaceuticals 
manufacturing. They are used for the delivery of large molecules, fragile 
molecules such as proteins, vaccines, antibiotics, hormones, gene 
therapy, and anticancer drugs. The involvement of chitosan-loaded 
anticancer agents to formulate new drug delivery systems can lead to 
novel features of the nanoparticles, which might be explained partly 
due to the high surface area of the active ingredients delivery over the 
bulk properties [37].
Chitosan is as natural, mucoadhesive, nontoxic, biodegradable [38], and 
biocompatible polymer [39,40]. It is a product of chitin deacetylation 
and found in the exoskeleton of crustaceans. Due to chitosan’s physical 
and chemical properties, its microspheres have many pharmaceutical 
applications [41,42]. Chitosan microspheres are used as a drug carrier 
to enhance the bioavailability of various drugs to get optimum drug 
release at specific site in the body. Furthermore, chitosan microspheres 
can be used in the formulation of either parenteral or oral drug delivery 
systems. Moreover, chitosan and its derivatives have the ability to be 
easily cross-linked with other molecules to synthesize fine particulates 
that can be utilized as effective drug carrier systems [43]. The process 
involves covalent binding of chitosan side chains with many functional 
cross-linking molecules, including glutaraldehyde and polyethylene 
glycol [44,45].
There are various advantages for the chitosan microspheres, including 
controlled drug release pattern that may be either constant or 
pulsatile [46], decrease the toxicity of drugs, overcome the problems 
associated with hydrophilic or hydrophobic drugs, and better patient 
compliance. This type of formulation can be used as injectable 
sustained drug delivery system and help the patients to avoid frequent 
doses [30]; it also improves drug absorption due to the increased in vitro 
adhesion [38]. Furthermore, chitosan microspheres are used to enhance 
drug delivery through the blood–brain barrier [47], where Hassan and 
Gallo in 1993 showed that the bioavailability of oxantrazole-loaded 
chitosan microspheres could be enhanced in the brain tissue [48]. On 
the other hand, microspheres have a few disadvantages. They are hard 
to maintain the effectiveness of the drug during the production process, 
it is difficult to produce large quantities and expensive to produce [30].
CHITOSAN MICROSPHERES FOR THE DRUG DELIVERY OF PTX
PTX is a natural and hydrophobic anticancer agent. It has been 
discovered by the National Cancer Institute in 1960 [1]. It is extracted 
from the bark of the pacific yew tree Taxus brevifolia [49]. PTX is an 
influential antitumor drug against ovarian cancer, breast cancer, 
head and neck cancer, lung cancer [50], leukemias, melanoma, and 
esophageal adenocarcinoma [51,52]. Although PTX is a highly cytotoxic 
drug, it has limited clinical applications because of low aqueous 
solubility (<1 µg/ml) [23]. The solubility problem is due to inherited 
physicochemical properties. PTX structure consists of a fused ring system 
and many hydrophobic substituents [53], and there are no functional 
ionizable groups. However, PTX is available as sterile non-aqueous 
solutions consist of Cremophore and ethanol [54]. Unfortunately, this 
formulation has been observed to induce many adverse effects such 
as hypersensitivity and neurotoxicity [55]. Due to the problems of 
poor solubility and adverse effects associated with the available PTX 
formulation, scientists are trying to formulate it in many alternative 
and effective drug delivery systems, such as cyclodextrin [56,57], 
dendrimers [58], nanoparticles [59], prodrugs [60,61], liposomes [62], 
2-methacryloyloxyethl phosphorylcholine polymers [63], and 
microspheres [64,65]. Moreover, a study performed by Mita et al. 
involved a new drug delivery system devoid of cremophore and 
composed of porous PTX microspheres [66].
In addition to chitosan loaded PTX microspheres formulation, PTX was 
incorporated in many other forms of chitosan-based delivery system 
formulations. The technique of loading PTX on chitosan involves 
physical complex formation rather than change of the drug loading 
on the nanoparticles. This approach provides most selective and safe 
delivery system for PTX [67]. A thermos-gelling solution of chitosan-
β-glycerophosphate salt and PTX was used as a local delivery system 
to prevent local recurrence of malignant tumors, without associated 
inflation and hyperthermia reported with parenteral formulation [68]. 
Furthermore, a hydrogel formula of PTX-loaded chitosan effectively 
decreases the number of CD34-positive vessels in subcutaneous 3LL 
tumors, indicating a strong inhibition of angiogenesis and tumor 
growth [69]. A PTX-loaded chitosan as thermos-sensitive hydrogel, 
which was modified by glutaraldehyde and polyvinyl alcohol for 
intratumoral delivery, was found as a promising approach to achieve 
effective sustained release and enhanced chemotherapeutic activity 
through in situ tumor injectable administration [70]. Recently, a new 
type of chitosan-based binary-copolymer systems containing PTX-
loaded micelles and siRNA-loaded LDL could directly deliver siRNA 
and PTX to cancer cells, offering promising chances to overcome 
the problem of multidrug resistance in cancer cells [71]. Moreover, 
parenteral nanocomposite hydrogel containing PEGylated gold 
nanorods and PTX-loaded chitosan was developed to improve local 
tumor control and found to have superior effects on preventing 
tumor recurrence and improving survival in the HepS-bearing mice, 
compared with photo-thermal therapy alone [72]. It has been also 
shown that PTX incorporated into polymeric micelles based on 
tocopherol succinate-chitosan-polyethylene glycol-folic acid micelle 
is a potential drug delivery system of PTX for the effective treatment 
of the tumor and reduction of systemic toxicity, which may provide a 
useful alternative formula for intravenous administration of PTX [73]. 
Among the different studied drug carriers, microparticles particularly 
chitosan-based microparticles have been used to enhance the solubility 
of anticancer drugs such as oxantrazole [74], PTX [65], and MTX [75].
Microspheres have been approved to enhance the solubility, dissolution 
rate, and bioavailability of PTX [65,76]. Al-shdefat et al. demonstrated 
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that chitosan microspheres influence the dissolution of PTX [65]. 
The presence of PTX in porous, amorphous form and small particle 
size in the microspheres further enhances its dissolution. The high 
zeta potential values of the particles allow maintenance of their low 
particle sizes, which prevent aggregation of the microparticles and 
increase PTX dissolution rate. It has been previously reported that 
the medium molecular weight of chitosan formulae exhibited the 
highest PTX dissolution rate because of the highest aqueous perfusable 
microspheres [65,77], where 90% of the drug could be released from 
the nanosuspension.
In addition to enhancing the solubility and dissolution rate of PTX, 
chitosan microspheres have also been demonstrated to entrap high 
percentages of PTX. Kollipara et al. have measured the entrapment 
efficiency of PTX in chitosan microspheres utilizing high-performance 
liquid chromatography. Different formulas have demonstrated 
different entrapment efficiencies of PTX depending on the molecular 
weight of chitosan and pH of the formulation and it was between 
21-83.7% [78]. Moderate acidic medium (pH 3-5) is the ideal cross-
linking media to get the highest entrapment efficiencies of PTX 
(83%, 83.7%, and 73.7%) [65,79]. Moreover, it has been reported 
that the highest entrapment efficiencies of PTX when incorporated 
in poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-
PLA) microspheres were 81.55, 81.53, and 73.93%. Furthermore, the 
reported PTX entrapment efficiencies in microspheres were higher 
than the entrapment efficiencies in other types of carrier systems 
such as liposomes (61.02±1.61%) [62] and gelatin nanoparticles 
(25%) [80].
In this regard, many investigators have also studied the release pattern 
of PTX from chitosan microspheres. They found that PTX release 
pattern was rapid in the first hour; then, the cumulative release amount 
was increased within 24 hrs [65], and the drug release pattern varies 
between different microspheres formulae. They specifically considered 
the microspheres’ particle size and the amorphous form of PTX as the 
two major factors that influence both dissolution and release pattern 
of PTX. Thus, the smaller particle sizes exhibited the highest drug 
release profiles. Moreover, the viscosity of chitosan could affect the 
release pattern of the drug with consequent impact on the biological 
activity [81,82]. It has been demonstrated also that increasing the 
film thickness of chitosan decreases the release pattern of a drug [83], 
in addition to the influence of the medium condition that affects the 
release pattern of PTX from microspheres [84]. Cho et al. studied the 
in vitro drug release pattern of PTX loaded chitosan microspheres in 
sodium salicylate as a medium and found that the solubility of PTX 
could be enhanced by 100 times in sodium salicylate without damaging 
the micellar structure of polymeric micelle drug delivery [84]. Although 
Al-shdefat et al. study involved PTX loaded chitosan microspheres 
and considered the only study in this regard, there are various studies 
which involve using other polymers with microspheres such as chitin 
microparticles [65,85], chitosan poly(lactic-co-glycolic acid) (PLGA) 
microparticles [22], PLA-PEG-PLA microspheres [79], PLA and ethylene 
vinyl acetate copolymer [63], and PTX-loaded PLGA microspheres 
containing isopropyl myristate [86].
CONCLUSION
This critical review has explained the delivery of PTX loaded chitosan 
microspheres. This drug delivery system has been designed to enhance 
PTX delivery at the tumor site and to reduce its side effects. The 
most significant finding in this review is that PTX limitations can be 
effectively avoided through incorporation in chitosan microspheres; 
thus, improving its solubility, dissolution rate, entrapment efficiency, 
and its release pattern. Accordingly, chitosan microspheres represent a 
promising future for the delivery of PTX.
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